{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:10:04Z","timestamp":1790626204328,"version":"4.1.0"},"reference-count":62,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5,1]]},"abstract":"\n OBJECTIVE:<\/jats:title>\n Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder characterized by insufficiency of the iduronate-2-sulfatase enzyme, which results in excess heparan and dermatan sulfates within the lysosomes of various tissues and organs, including the central nervous system. The purpose of this study was to investigate the natural progression of neurologic disease in a large cohort of patients evaluated with standardized testing at a single institution.<\/jats:p>\n <\/jats:sec>\n \n METHODS:<\/jats:title>\n During the period of December 2002 to October 2010, patients with MPS II were referred to the Program for Neurodevelopmental Function in Rare Disorders. A retrospective review of patient data was performed, which included the use of detailed questionnaires that addressed medical history, notes from previous health care providers, and the results of a multidisciplinary evaluation that lasted 4 to 6 hours and was performed by a team of neurodevelopmental pediatricians, speech pathologists, psychologists, audiologists, psychometricians, and occupational and physical therapists. Patients were evaluated annually for management of disease progression.<\/jats:p>\n <\/jats:sec>\n \n RESULTS:<\/jats:title>\n A total of 50 male patients with MPS II were evaluated over 152 encounters. Two distinct subgroups of children were identified. One subset of patients had normal cognitive, speech and language, and adaptive functions whereas the other showed a dramatic decline in these areas. All patients developed fine and gross motor deficits.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSION:<\/jats:title>\n The natural progression of MPS II manifests as 2 divergent and distinct neurologic phenotypes with similar somatic disease. Patients may have primary neural parenchymal disease with cognitive involvement or may maintain normal cognitive abilities.<\/jats:p>\n <\/jats:sec>","DOI":"10.1542\/peds.2010-1274","type":"journal-article","created":{"date-parts":[[2011,4,25]],"date-time":"2011-04-25T22:29:48Z","timestamp":1303770588000},"page":"e1258-e1265","source":"Crossref","is-referenced-by-count":106,"title":["Natural Progression of Neurological Disease in Mucopolysaccharidosis Type II"],"prefix":"10.1542","volume":"127","author":[{"given":"Joshua B.","family":"Holt","sequence":"first","affiliation":[{"name":"University of North Carolina School of Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele D.","family":"Poe","sequence":"additional","affiliation":[{"name":"Frank Porter Graham Child Development Institute, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Escolar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2011,5,1]]},"reference":[{"key":"2021121006550010300_B1","first-page":"3421","article-title":"The mucopolysaccharidoses","volume-title":"The Metabolic and Molecular Bases of Inherited Disease","author":"Neufeld","year":"2001"},{"issue":"3","key":"2021121006550010300_B2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/BF00206770","article-title":"An update on the frequency of mucopolysaccharide syndromes in British Columbia","volume":"85","author":"Lowry","year":"1990","journal-title":"Hum Genet"},{"issue":"4","key":"2021121006550010300_B3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF00569230","article-title":"Incidence of Hunter's syndrome","volume":"60","author":"Young","year":"1982","journal-title":"Hum Genet"},{"issue":"2","key":"2021121006550010300_B4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00295699","article-title":"Incidence of mucopolysaccharidoses in Israel: is Hunter disease a \u201cJewish disease\u201d?","volume":"56","author":"Schaap","year":"1980","journal-title":"Hum Genet"},{"issue":"3","key":"2021121006550010300_B5","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"issue":"6","key":"2021121006550010300_B6","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s10545-005-0112-z","article-title":"Cumulative incidence rates of the mucopolysaccharidoses in Germany","volume":"28","author":"Baehner","year":"2005","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"2021121006550010300_B7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s004399900075","article-title":"The frequency of lysosomal storage diseases in the Netherlands","volume":"105","author":"Poorthuis","year":"1999","journal-title":"Hum Genet"},{"issue":"11","key":"2021121006550010300_B8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/adc.58.11.911","article-title":"Hunter's disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene","volume":"58","author":"Mossman","year":"1983","journal-title":"Arch Dis Child"},{"issue":"5","key":"2021121006550010300_B9","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1399-0004.1990.tb03519.x","article-title":"Hunter disease (mucopolysaccharidosis type II) in a karyotypically normal girl","volume":"37","author":"Clarke","year":"1990","journal-title":"Clin Genet"},{"issue":"5","key":"2021121006550010300_B10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1098-1004(1997)10:5<361::AID-HUMU5>3.0.CO;2-I","article-title":"Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele","volume":"10","author":"Sukegawa","year":"1997","journal-title":"Hum Mutat"},{"issue":"6","key":"2021121006550010300_B11","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/ajmg.1320440625","article-title":"Female twin with Hunter disease due to nonrandom inactivation of the X-chromosome: a consequence of twinning","volume":"44","author":"Winchester","year":"1992","journal-title":"Am J Med Genet"},{"issue":"4","key":"2021121006550010300_B12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of Hunter's syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"2021121006550010300_B13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1517\/14656566.9.2.311","article-title":"Idursulfase for the treatment of mucopolysaccharidosis II","volume":"9","author":"Clarke","year":"2008","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"2021121006550010300_B14","first-page":"425","article-title":"Clinical and probable genetic heterogeneity within mucopolysaccharidosis, II: report of a family with a mild form","volume":"131","author":"Lichtenstein","year":"1972","journal-title":"Johns Hopkins Med J"},{"issue":"6","key":"2021121006550010300_B15","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/jmg.19.6.408","article-title":"A clinical and genetic study of Hunter's syndrome: 2 differences between the mild and severe forms","volume":"19","author":"Young","year":"1982","journal-title":"J Med Genet"},{"issue":"2","key":"2021121006550010300_B16","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"2021121006550010300_B17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/humu.1169","article-title":"Molecular analysis of 40 Italian patients with mucopolysaccharidosis type II: new mutations in the iduronate-2-sulfatase (IDS) gene","volume":"18","author":"Filocamo","year":"2001","journal-title":"Hum Mutat"},{"issue":"5","key":"2021121006550010300_B18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/hmg\/1.5.335","article-title":"Mutation analysis of the iduronate-2-sulfatase gene in patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Bunge","year":"1992","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2021121006550010300_B19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/hmg\/4.4.615","article-title":"Inversion of the IDS gene resulting from recombination with IDS-related sequences is a common cause of the Hunter syndrome","volume":"4","author":"Bondeson","year":"1995","journal-title":"Hum Mol Genet"},{"issue":"439","key":"2021121006550010300_B20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1651-2227.2002.tb03116.x","article-title":"Mucopolysaccharidosis type II: genotype\/phenotype aspects","volume":"91","author":"Froissart","year":"2002","journal-title":"Acta Paediatr Suppl"},{"issue":"6","key":"2021121006550010300_B21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1005432600871","article-title":"Hunter disease in the Spanish population: molecular analysis in 31 families","volume":"21","author":"Gort","year":"1998","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2021121006550010300_B22","first-page":"21","article-title":"Molecular basis of iduronate- 2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome)","volume":"36","author":"Li","year":"1999","journal-title":"J Med Genet"},{"issue":"3","key":"2021121006550010300_B23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/adc.79.3.237","article-title":"Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease)","volume":"79","author":"Vafiadaki","year":"1998","journal-title":"Arch Dis Child"},{"issue":"3","key":"2021121006550010300_B24","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/hmg\/6.3.479","article-title":"Molecular and phenotypic variation in patients with severe Hunter syndrome","volume":"6","author":"Timms","year":"1997","journal-title":"Hum Mol Genet"},{"issue":"1","key":"2021121006550010300_B25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ymgme.2003.11.002","article-title":"Iduronate- 2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients","volume":"81","author":"Parkinson","year":"2004","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2021121006550010300_B26","first-page":"653","article-title":"Longterm follow-up of a patient transplanted for Hunter's disease type IIB: a case report and literature review","volume":"14","author":"Bergstrom","year":"1994","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2021121006550010300_B27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF01800340","article-title":"Attempted enzyme replacement using human amnion membrane implantations in mucopolysaccharidoses","volume":"15","author":"Muenzer","year":"1992","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2021121006550010300_B28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1172\/JCI109267","article-title":"Enzyme replacement therapy by fibroblast transplantation: long-term biochemical study in three cases of Hunter's syndrome","volume":"63","author":"Dean","year":"1979","journal-title":"J Clin Invest"},{"issue":"8","key":"2021121006550010300_B29","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1073\/pnas.68.8.1738","article-title":"Effect of leukocyte transfusion in a child with type II mucopolysaccharidosis","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2021121006550010300_B30","first-page":"802","article-title":"A therapeutic trial of fresh plasma infusions over a period of 22 months in two siblings with Hunter's syndrome","volume":"11","author":"Yatziv","year":"1975","journal-title":"Isr J Med Sci"},{"issue":"7","key":"2021121006550010300_B31","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/hmg\/ddl038","article-title":"Correction of Hunter syndrome in the MPS II mouse model by AAV2\/8-mediated gene delivery","volume":"15","author":"Cardone","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"439","key":"2021121006550010300_B32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1651-2227.2002.tb03119.x","article-title":"Nonviral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome)","volume":"91","author":"Tomanin","year":"2002","journal-title":"Acta Paediatr Suppl"},{"issue":"4","key":"2021121006550010300_B33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1537-2995.1999.39499235664.x","article-title":"Retroviral transduction and expansion of peripheral blood lymphocytes for the treatment of mucopolysaccharidosis type II, Hunter's syndrome","volume":"39","author":"Stroncek","year":"1999","journal-title":"Transfusion"},{"issue":"11","key":"2021121006550010300_B34","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/jgm.790","article-title":"Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts","volume":"7","author":"Friso","year":"2005","journal-title":"J Gene Med"},{"issue":"3","key":"2021121006550010300_B35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol Genet Metab"},{"issue":"8","key":"2021121006550010300_B36","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) [published correction appears in Genet Med. 2006;8(9):599]","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med"},{"key":"2021121006550010300_B37","first-page":"S124","article-title":"Novel treatments and future perspectives: outcomes of intrathecal drug delivery","volume":"47","author":"Dickson","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1\u20132","key":"2021121006550010300_B38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2004.07.003","article-title":"Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I","volume":"83","author":"Kakkis","year":"2004","journal-title":"Mol Genet Metab"},{"issue":"19","key":"2021121006550010300_B39","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1056\/NEJMoa032613","article-title":"Cord-blood transplants from unrelated donors in patients with Hurler's syndrome","volume":"350","author":"Staba","year":"2004","journal-title":"N Engl J Med"},{"issue":"20","key":"2021121006550010300_B40","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa042604","article-title":"Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease","volume":"352","author":"Escolar","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"2021121006550010300_B41","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.bbmt.2007.01.082","article-title":"Outcomes of unrelated umbilical cord blood transplantation for X-linked adrenoleukodystrophy","volume":"13","author":"Beam","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021121006550010300_B42","volume-title":"The Mullen Scales of Early Learning","author":"Mullen","year":"1995"},{"key":"2021121006550010300_B43","volume-title":"The Differential Ability Scale (DAS)","author":"Elliot","year":"1979"},{"key":"2021121006550010300_B44","volume-title":"Leiter International Performance Scale, Revised Manual","author":"Roid","year":"1997"},{"key":"2021121006550010300_B45","volume-title":"Scales of Independent Behavior, Revised: Comprehensive Manual","author":"Bruininks","year":"1996"},{"key":"2021121006550010300_B46","volume-title":"Pediatric Evaluation of Disability Inventory (PEDI)","author":"Hayley","year":"1992"},{"key":"2021121006550010300_B47","volume-title":"Preschool Language Scale","author":"Zimmerman","year":"2002","edition":"4th ed."},{"key":"2021121006550010300_B48","volume-title":"Receptive-Expressive Emergent Language","author":"Bzoch","year":"2003","edition":"3rd ed."},{"key":"2021121006550010300_B49","volume-title":"Clinical evaluation of language fundamentals","author":"Semel","year":"2003","edition":"4th ed."},{"key":"2021121006550010300_B50","volume-title":"Peabody Developmental Motor Scales","author":"Folio","year":"2000","edition":"2nd ed."},{"issue":"457","key":"2021121006550010300_B51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1651-2227.2008.00651.x","article-title":"Methods for assessing neurodevelopment in lysosomal storage diseases and related disorders: a multidisciplinary perspective","volume":"97","author":"Martin","year":"2008","journal-title":"Acta Paediatrica"},{"issue":"16","key":"2021121006550010300_B52","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.286.16.2000","article-title":"Universal newborn hearing screening: summary of evidence","volume":"286","author":"Thompson","year":"2001","journal-title":"JAMA"},{"issue":"9145","key":"2021121006550010300_B53","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/S0140-6736(98)06359-4","article-title":"Controlled trial of universal neonatal screening for early identification of permanent childhood hearing impairment","volume":"352","author":"Wessex University Neonatal Hearing Screening Trial Group","year":"1998","journal-title":"Lancet"},{"key":"2021121006550010300_B54","volume-title":"Behavioral and Developmental Pediatrics: A Handbook for Primary Care","author":"Parker","year":"2005","edition":"2nd ed."},{"issue":"457","key":"2021121006550010300_B55","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1651-2227.2008.00646.x","article-title":"Magnetic resonance imaging findings in Hunter syndrome","volume":"97","author":"Finn","year":"2008","journal-title":"Acta Paediatr"},{"issue":"4","key":"2021121006550010300_B56","first-page":"273","article-title":"Prospective study of 11 Brazilian patients with mucopolysaccharidosis II","volume":"82","author":"Pinto","year":"2006","journal-title":"J Pediatr (Rio J)"},{"issue":"2\u20133","key":"2021121006550010300_B57","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10545-006-0265-4","article-title":"Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders","volume":"29","author":"Gelb","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2021121006550010300_B58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1373\/clinchem.2006.077263","article-title":"Tandem mass spectrometry for the direct assay of enzymes in dried blood spots: Application to newborn screening for mucopolysaccharidosis II (Hunter disease)","volume":"53","author":"Wang","year":"2007","journal-title":"Clin Chem"},{"issue":"12","key":"2021121006550010300_B59","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/clinchem\/47.12.2098","article-title":"Hurler-like phenotype: enzymatic diagnosis in dried blood spots on filter paper","volume":"47","author":"Chamoles","year":"2001","journal-title":"Clin Chem"},{"issue":"4","key":"2021121006550010300_B60","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1542\/peds.2004-0583","article-title":"Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy","volume":"114","author":"Meikle","year":"2004","journal-title":"Pediatrics"},{"issue":"2","key":"2021121006550010300_B61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/j.semperi.2009.12.008","article-title":"Digital microfluidics: a future technology in the newborn screening laboratory?","volume":"34","author":"Millington","year":"2010","journal-title":"Semin Perinatol"},{"issue":"5","key":"2021121006550010300_B62","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.braindev.2006.08.015","article-title":"Evaluation of ADL in patients with Hunter disease using FIM score","volume":"29","author":"Kato","year":"2007","journal-title":"Brain Dev"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/5\/e1258\/909005\/zpe005110e1258.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/127\/5\/e1258\/909005\/zpe005110e1258.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T10:58:31Z","timestamp":1639133911000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/127\/5\/e1258\/64876\/Natural-Progression-of-Neurological-Disease-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,1]]},"references-count":62,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2011,5,1]]},"published-print":{"date-parts":[[2011,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2010-1274","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,1]]}}}